Evaluating alpha-blocker therapy for managing urinary symptoms after prostate surgery
Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy
This study is testing if the medication Tamsulosin can help men feel better by reducing painful and bothersome urinary symptoms after prostate surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 82 (estimated) |
| Ages | 40 Years to 85 Years |
| Sex | Male |
| Sponsor | Ankara Training and Research Hospital Academic / other |
| Locations | 1 site (Ankara) |
| Trial ID | NCT06865430 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of alpha-blocker therapy, specifically Tamsulosin Hydrochloride, in alleviating dysuria and irritative urinary symptoms following Holmium Laser Enucleation of the Prostate (HoLEP) for benign prostatic hyperplasia (BPH). It aims to address the common postoperative complications that affect patient quality of life, which occur in a significant percentage of patients within the first three months after surgery. By comparing the effects of the medication against a sham treatment, the study seeks to provide evidence on the potential benefits of alpha-blockers in this context.
Who should consider this trial
Good fit: Ideal candidates for this study are men aged between 40 and 85 who have undergone HoLEP surgery.
Not a fit: Patients with prostate cancer, bladder stones, or a history of urethral stricture may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the management of postoperative urinary symptoms, enhancing patient satisfaction and quality of life.
How similar studies have performed: Previous studies have shown varying success with similar approaches, but this specific evaluation of alpha-blockers post-HoLEP is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Men over 40 years old, under 85 years old, and HoLEP surgery Exclusion Criteria: Prostate cancer, patients with bladder stones, patients with a history of urethral stricture, patients with detrusor underactivity in urodynamics, those who have had prostate surgery before
Where this trial is running
Ankara
- Ankara bilkent city hospital — Ankara, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Kazım Ceviz
- Email: kazimmzz@hotmail.com
- Phone: 312 552 66 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.